⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNTH News
Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
globenewswire.com
DNTH
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
globenewswire.com
DNTH
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
globenewswire.com
DNTH